Clearly, our findings should be confirmed in larger series to investigate the impact of KRAS mutation detection on clinical decisions, with particular regard to selection of patients for combination treatments, currently under investigation in lung cancer, such as EGFR inhibitor plus chemotherapy or plus antiangiogenic treatment (35). The gene discussed is EGFR; the disease is lung carcinoma.